Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Wall Street Analyst Weigh In
INGN has been the subject of a number of analyst reports. Stifel Nicolaus reduced their target price on shares of Inogen from $40.00 to $30.00 in a research note on Monday, May 9th. StockNews.com raised shares of Inogen from a "sell" rating to a "hold" rating in a research note on Friday, August 5th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $41.00.
Inogen Stock Performance
Shares of NASDAQ:INGN opened at $27.61 on Wednesday. The company has a 50 day moving average of $26.39 and a 200-day moving average of $28.38. The firm has a market cap of $631.33 million, a P/E ratio of -22.09 and a beta of 1.02. Inogen has a twelve month low of $22.51 and a twelve month high of $65.60.
Inogen (NASDAQ:INGN - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The medical technology company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.24. The company had revenue of $103.38 million during the quarter, compared to analyst estimates of $100.64 million. Inogen had a negative net margin of 8.03% and a negative return on equity of 5.35%. The business's revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.22 EPS. Equities research analysts forecast that Inogen will post -1.61 EPS for the current year.